Clinical features associated with ADB-BUTINACA exposure in patients attending emergency departments in England.

A KingS L HillM PucciG BaileyLiza KeatingR MacfarlaneF CantleS HudsonSimon Hugh Lynton Thomas

Published in: Clinical toxicology (Philadelphia, Pa.) (2022)

ADB-BUTINACA has recently emerged as a drug of misuse in England. Clinical features of toxicity are consistent with those of other SCRA and include reduced level of consciousness, respiratory and/or metabolic acidosis, seizures, confusion and hallucinations.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
chronic pain
emergency department
patient reported outcomes